医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2012年
32期
188-189
,共2页
布地奈德%可必特%联合治疗%慢阻肺急性发作
佈地奈德%可必特%聯閤治療%慢阻肺急性髮作
포지내덕%가필특%연합치료%만조폐급성발작
budesonide%combivent%combination%therapy%chronic obstructive pulmonary disease acute exacerbation
目的探讨布地奈德、可必特联合治疗慢阻肺急性发作的临床疗效.方法选取本院2010年2月到2011年2月期间本院收治的慢阻肺急性发作患者122例,随机分成观察组61例,对照组61例,给予对照组可必特治疗,给予观察组布地奈德联合可必特治疗,比较两组患者的临床疗效.结果对照组治疗前生活质量评分为(61.21±6.53)分,治疗后生活质量评分(47.43±7.38)分,住院时间(18.87±4.21)日;观察组治疗前生活质量评分为(60.98±7.21)分,治疗后生活质量评分(44.35±6.58)分,住院时间(14.32±3.83)日.两组患者在治疗后生活质量评分和住院时间方面具有显著性差异,P<0.05,有统计学意义.结论布地奈德、可必特联合治疗慢阻肺急性发作具有确切的临床疗效,值得临床推广使用.
目的探討佈地奈德、可必特聯閤治療慢阻肺急性髮作的臨床療效.方法選取本院2010年2月到2011年2月期間本院收治的慢阻肺急性髮作患者122例,隨機分成觀察組61例,對照組61例,給予對照組可必特治療,給予觀察組佈地奈德聯閤可必特治療,比較兩組患者的臨床療效.結果對照組治療前生活質量評分為(61.21±6.53)分,治療後生活質量評分(47.43±7.38)分,住院時間(18.87±4.21)日;觀察組治療前生活質量評分為(60.98±7.21)分,治療後生活質量評分(44.35±6.58)分,住院時間(14.32±3.83)日.兩組患者在治療後生活質量評分和住院時間方麵具有顯著性差異,P<0.05,有統計學意義.結論佈地奈德、可必特聯閤治療慢阻肺急性髮作具有確切的臨床療效,值得臨床推廣使用.
목적탐토포지내덕、가필특연합치료만조폐급성발작적림상료효.방법선취본원2010년2월도2011년2월기간본원수치적만조폐급성발작환자122례,수궤분성관찰조61례,대조조61례,급여대조조가필특치료,급여관찰조포지내덕연합가필특치료,비교량조환자적림상료효.결과대조조치료전생활질량평분위(61.21±6.53)분,치료후생활질량평분(47.43±7.38)분,주원시간(18.87±4.21)일;관찰조치료전생활질량평분위(60.98±7.21)분,치료후생활질량평분(44.35±6.58)분,주원시간(14.32±3.83)일.량조환자재치료후생활질량평분화주원시간방면구유현저성차이,P<0.05,유통계학의의.결론포지내덕、가필특연합치료만조폐급성발작구유학절적림상료효,치득림상추엄사용.
Objective: To investigate the effects of budesonide, combivent combined treatment of COPD acute clinical efficacy. Method: to select this hospital from 2010 February to 2011 February were treated in our hospital during the period of chronic obstructive pulmonary disease patients with acute onset in 122 cases, 61 cases were randomly divided into the observation group, 61 cases in the control group, the control group given combivent in the treatment group, to give observation of budesonide combined with combivent in the treatment, comparing the two groups of patients with clinical efficacy. Results: in the control group before treatment quality of life score was (61.21± 6.53), after treatment and quality of life score (47.43±7.38), (18.87±4.21) hospitalized time of day; observation group before treatment quality of life score was (60.98± 7.21), after treatment and quality of life score (44.35±6.58) branch, hospitalization time (14.32±3.83) days. Two groups of patients after treatment quality of life score and length of hospital stay have significant difference, P<0.05, with statistical significance. Conclusion: budesonide, combivent combined treatment of COPD acute episode has exact curative effect, it is worth for clinical use.